By examining aggregated mutation frequencies across all cancer types, we found that TP53 mutations were more prevalent across all cancer types in the meBRCA1 subgroup, with 66% of methylated cases harbouring a TP53 mutation compared to 43% of unmethylated cases (Supplementary Figure S14a). This evidence concerns the gene TP53 and cancer.